Form D · Biotechnology
Ikena Oncology, Inc.
Boston, MA · CIK 0001835579
Offering snapshot reported Jul 18, 2025 · SEC filing
- Reported sold
- Yet to sell Offering amount: $75M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 18, 2025 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 18, 2023 | Initial | $42,571,751 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-552269
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| LEERINK PARTNERS LLC | 39011 |
Source: Form D, filed Jul 18, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Bonita | Director |
| Iain Dukes | Director |
| Jeffrey Ecsedy | Executive |
| Jean Francois Formela | Director |
| Owen Hughes | Director |
| Maria Koehler | Director |
| Mark Manfredi | Director, Executive |
| Jotin Marango | Executive |
| Sergio Santillana | Executive |
| Otello Stampacchia | Director |
| Richard Wooster | Director |
| Michelle Zhang | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
645 Summer Street, Suite 101
Boston, MA, 02210
Boston, MA, 02210